Litigation (Details) - USD ($)					3 Months Ended					9 Months Ended		12 Months Ended
		Apr. 18, 2025	Feb. 06, 2025	Jul. 31, 2024	Sep. 30, 2025	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Dec. 31, 2022	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024	Jul. 02, 2024
Commitments and Contingencies Disclosure [Line Items]
Other assets					$ 11,600,000	$ 18,900,000				$ 11,600,000		$ 18,900,000
Revenue					231,100,000		$ 293,800,000			594,200,000	$ 848,900,000
Cost of goods and services sold	[1]				85,900,000		122,600,000			241,300,000	563,300,000
Product and services sales, net
Commitments and Contingencies Disclosure [Line Items]
Revenue					222,000,000.0		$ 283,800,000			561,400,000	$ 824,300,000
Jansen Pharmaceuticals, Inc.
Commitments and Contingencies Disclosure [Line Items]
Proceeds from legal settlements				$ 50,000,000
Increase in other assets									$ 152,700,000
Other assets						0						0	$ 158,700,000
Cost of goods and services sold								$ 50,000,000
Inventory Write-down								110,200,000
Jansen Pharmaceuticals, Inc. | Product and services sales, net
Commitments and Contingencies Disclosure [Line Items]
Revenue								$ 50,000,000
Securities And Shareholder Litigation
Commitments and Contingencies Disclosure [Line Items]
Damages paid						40,000,000
Damages paid from insurance proceeds						30,000,000
Settlement period			20 days
Settlement amount			$ 15,000,000
Implementation reforms, period			60 days
Period of reforms to be maintained			4 years
Settlement gain					10,500,000					10,500,000
SEC Enforcement Proceeding
Commitments and Contingencies Disclosure [Line Items]
Loss contingency accrual, provision												1,500,000
Payments for legal settlements		$ 1,500,000
Loss contingency, accrual, current					$ 0	$ 1,500,000				$ 0		$ 1,500,000

[1] (1) Exclusive of intangible asset amortization